InvestSMART

Cleo Diagnostics Ltd (ASX:COV)

ALERT: Price-sensitive ASX Announcement for COV
Current share price for COV : $0.360 -0.15 (-29.41%)+
Announcement
Release
13 Jul 2026 9:10AM
Price at Release
$0.510
Full Release
download
Summary
Cleo Diagnostics Ltd (ASX:COV) has announced its entry into the analytical validation phase, marking a significant milestone in its journey towards FDA submission. The company has completed the development of its commercial assay and is now focusing on the pre-FDA submission validation, expecting to commence validation next month with the first production batch of test kits from Bio-Techne. This phase involves a three-batch validation to ensure assay reproducibility and consistency, in line with FDA requirements. Cleo aims for FDA 510(k) submission in the first half of 2027 and is preparing for clinical validation through engagements with an external laboratory and finalizing protocols. The validation is expected to take about four months, subject to manufacturing timelines.
Key Points
  • CLEO has entered the analytical validation phase after completing commercial assay development.
  • The validation phase is crucial for pre-FDA submission, expected to start next month with the first batch of CLEO's test kits.
  • A three-batch validation design will be used to demonstrate assay reproducibility and manufacturing consistency.
  • CLEO plans to submit for FDA 510(k) approval in the first half of 2027.
  • Preparations for clinical validation are advancing, including engagement with an external laboratory and finalizing study protocols.
  • The clinical validation will involve samples from the pivotal U.S. clinical trial alongside confounding condition samples.
  • Subject to manufacturing timelines, analytical validation is expected to take approximately four months.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.